Response by baseline BCR-ABL mutation analysis
| Imatinib-resistant mutation . | No. (%) of patients at 8 months' follow-up . | ||
|---|---|---|---|
| Total* . | MaHR . | MCyR . | |
| None | 7 (22) | 2/7 (29) | 4/7 (57) |
| Any | 25 (78) | 11/25 (44) | 14/25 (56) |
| P-loop; amino acids 248-255 | 11 (34) | 4/11 (36) | 5/11 (45) |
| A-loop; amino acids 379-398 | 3 (9) | 3/3 (100) | 3/3 (100) |
| Other regions | 11 (34) | 4/11 (36) | 6/11 (55) |
| Specific mutations† | |||
| M244V | 2 | 1 | 1 |
| G250E | 4 | 1 | 2 |
| Y253H | 3 | 3 | 2 |
| E255K | 4 | 0 | 1 |
| D276G | 2 | 2 | 2 |
| T315I | 6 | 0 | 0 |
| E355G | 2 | 0 | 0 |
| H396P | 2 | 2 | 2 |
| F486S | 2 | 1 | 2 |
| Imatinib-resistant mutation . | No. (%) of patients at 8 months' follow-up . | ||
|---|---|---|---|
| Total* . | MaHR . | MCyR . | |
| None | 7 (22) | 2/7 (29) | 4/7 (57) |
| Any | 25 (78) | 11/25 (44) | 14/25 (56) |
| P-loop; amino acids 248-255 | 11 (34) | 4/11 (36) | 5/11 (45) |
| A-loop; amino acids 379-398 | 3 (9) | 3/3 (100) | 3/3 (100) |
| Other regions | 11 (34) | 4/11 (36) | 6/11 (55) |
| Specific mutations† | |||
| M244V | 2 | 1 | 1 |
| G250E | 4 | 1 | 2 |
| Y253H | 3 | 3 | 2 |
| E255K | 4 | 0 | 1 |
| D276G | 2 | 2 | 2 |
| T315I | 6 | 0 | 0 |
| E355G | 2 | 0 | 0 |
| H396P | 2 | 2 | 2 |
| F486S | 2 | 1 | 2 |